Efficacy and safety of antiplatelet-combination therapy after drug-eluting stent implantation

다국어 초록 (Multilingual Abstract)

Background/Aims: Combination single-pill therapy can improve cost-effectivenessin a typical medical therapy. However, there is a little evidence about theefficacy and tolerability of combination single-pill antiplatelet therapy after percutaneouscoronary intervention (PCI) with drug-eluting stents (DES).
Methods: From June to November 2012, in total, 142 patients who met the followingcriteria were enrolled: at least 18 years old; successful PCI with DES at least 3months earlier; and regular medication of aspirin and clopidogrel with no sideeffects. After VerifyNow P2Y12 and aspirin assays, the combination single pill ofaspirin and clopidogrel was given and laboratory tests were repeated 6 weeks later.
Results: At baseline, the incidence of aspirin resistance, defined as aspirin reactionunit (ARU) ≥ 550, was 9.2%, that of clopidogrel resistance, defined as P2Y12reaction unit (PRU) ≥ 230, was 46.5%, and that of percent inhibition of PRU <20% was 32.4%. At follow-up, the incidence of resistance by ARU value was 7.0%,50.0% by PRU value, and 35.9% by percentage inhibition of PRU, respectively. Themean values of ARU (431.5 ± 63.6 vs. 439.8 ± 55.2; p = 0.216) and PRU (227.5 ± 71.4vs. 223.3 ± 76.0; p = 0.350) were not significantly different before versus after antiplatelet-combination single-pill therapy. Five adverse events (3.5%) were observedduring the study period.
Conclusions: Combination single-pill antiplatelet therapy, which may reduce dailypill burden for patients after PCI with DES, demonstrated similar efficacy toseparate dual-pill antiplatelet therapy.

참고문헌 (Reference)

1 김성환, "약물방출 스텐트의 최근 동향" 대한내과학회 75 (75): 370-382, 2008

2 "Ultegra Rapid Platelet Function Assay-ASA (RPFA-ASA)" Accumetrics Inc. 2002

3 Panjabi S, "Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients" 7 : 46-60, 2013

4 Shim CY, "The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation" 134 : 351-355, 2009

5 Takayama T, "Stent thrombosis and drug-eluting stents" 58 : 92-98, 2011

6 Sherrill B, "Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence" 13 : 898-909, 2011

7 Campo G, "Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome" 57 : 2474-2483, 2011

8 Zamorano J, "Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial" 27 : 821-833, 2011

9 Price MJ, "Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay. Impact on Thrombosis and Safety (GRAVITAS) trial" 124 : 1132-1137, 2011

10 Suh JW, "Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial" 57 : 280-289, 2011

11 Jin HY, "High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting" 167 : 1877-1881, 2013

12 Devabhaktuni M, "Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives" 5 : 377-387, 2009

13 European Association for Cardiovascular Prevention &Rehabilitation, "ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)" 32 : 1769-1818, 2011

14 Ahn SG, "Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction" 5 : 259-267, 2012

15 Garg S, "Coronary stents: current status" 56 (56): S1-S42, 2010

16 Gupta AK, "Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis" 55 : 399-407, 2010

17 Cohen M, "Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond" 74 : 579-597, 2009